CSL secures access to mRNA vaccine technology
Biotechnology and vaccine manufacturer CSL has licensed late stage self-amplifying mRNA vaccine platform technology from global vaccine developer Arcturus Therapeutics Holdings. Arcturus is developing next generation mRNA vaccines including a Covid-19 vaccine candidate that recently reported results from a major Phase 3 vaccine efficacy study. The vaccine candidate met its clinical goals in the study…
Details